|
US3854480A
(en)
|
1969-04-01 |
1974-12-17 |
Alza Corp |
Drug-delivery system
|
|
US4675189A
(en)
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
|
US4452775A
(en)
|
1982-12-03 |
1984-06-05 |
Syntex (U.S.A.) Inc. |
Cholesterol matrix delivery system for sustained release of macromolecules
|
|
US5075109A
(en)
|
1986-10-24 |
1991-12-24 |
Southern Research Institute |
Method of potentiating an immune response
|
|
US5211657A
(en)
|
1988-11-07 |
1993-05-18 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
|
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
|
US5032401A
(en)
|
1989-06-15 |
1991-07-16 |
Alpha Beta Technology |
Glucan drug delivery system and adjuvant
|
|
US5407686A
(en)
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
|
EP0804249A2
(en)
|
1994-03-15 |
1997-11-05 |
Brown University Research Foundation |
Polymeric gene delivery system
|
|
US5736152A
(en)
|
1995-10-27 |
1998-04-07 |
Atrix Laboratories, Inc. |
Non-polymeric sustained release delivery system
|
|
WO1997033623A1
(en)
*
|
1996-03-15 |
1997-09-18 |
University Of Florida |
OLIGONUCLEOTIDES TARGETED TO ANGIOTENSINOGEN mRNA
|
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
|
US8273866B2
(en)
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
|
EP1432724A4
(en)
|
2002-02-20 |
2006-02-01 |
Sirna Therapeutics Inc |
RNA inhibition mediated inhibition of MAP KINASE GENES
|
|
EP2305813A3
(en)
|
2002-11-14 |
2012-03-28 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
WO2005013901A2
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
|
CA2566286A1
(en)
|
2004-05-11 |
2005-12-08 |
Rnai Co., Ltd. |
Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
|
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
WO2006081192A2
(en)
|
2005-01-24 |
2006-08-03 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of the nogo-l or nogo-r gene and uses thereof
|
|
CN101292034A
(zh)
|
2005-09-15 |
2008-10-22 |
桑塔里斯制药公司 |
抑制apo-b100表达的rna拮抗化合物
|
|
CA2622583A1
(en)
|
2005-09-15 |
2007-03-22 |
Henrik Frydenlund Hansen |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
|
US20100137405A1
(en)
|
2007-05-02 |
2010-06-03 |
Merck & Co., Inc |
RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
KR20110110776A
(ko)
|
2008-12-18 |
2011-10-07 |
다이서나 파마수이티컬, 인크. |
유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
|
|
US11414664B2
(en)
|
2008-12-18 |
2022-08-16 |
Dicerna Pharmaceuticals, Inc. |
Extended dicer substrate agents and methods for the specific inhibition of gene expression
|
|
WO2010093788A2
(en)
|
2009-02-11 |
2010-08-19 |
Dicerna Pharmaceuticals, Inc. |
Multiplex dicer substrate rna interference molecules having joining sequences
|
|
WO2010111490A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
JP6010458B2
(ja)
|
2009-04-03 |
2016-10-19 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. |
非対称二本鎖rnaによる特異的阻害のための、方法および組成物
|
|
US20110196141A1
(en)
|
2009-09-07 |
2011-08-11 |
Council Of Scientific & Industrial Research |
Locked and unlocked 2'-o phosphoramidite nucleosides, process of preparation thereof and oligomers comprising the nucleosides
|
|
WO2011038356A2
(en)
|
2009-09-25 |
2011-03-31 |
Johns Hopkins University |
Novel liver-targeting agents and their synthesis
|
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
|
WO2012145582A2
(en)
|
2011-04-22 |
2012-10-26 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibitions of egfr by double-stranded rna
|
|
CN102260673A
(zh)
|
2011-07-12 |
2011-11-30 |
深圳职业技术学院 |
靶向人血管紧张素原的rna干扰片段、表达载体与应用
|
|
US9796974B2
(en)
|
2011-11-18 |
2017-10-24 |
Alnylam Pharmaceuticals, Inc. |
Modified RNAi agents
|
|
RU2624028C2
(ru)
|
2012-05-24 |
2017-06-30 |
Ионис Фармасьютикалз, Инк. |
Способы и композиции для модулирования экспрессии аполипопротеина (а)
|
|
EP3693460A1
(en)
*
|
2012-07-27 |
2020-08-12 |
Ionis Pharmaceuticals, Inc. |
Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
|
|
TWI553017B
(zh)
|
2012-12-28 |
2016-10-11 |
行政院原子能委員會核能研究所 |
新穎膽道掃描用造影劑及其製造方法
|
|
CN103103192A
(zh)
|
2013-01-18 |
2013-05-15 |
深圳职业技术学院 |
靶向血管紧张素原的rna干扰片段、其表达载体、混合克隆细胞株及其应用
|
|
EP2958998B1
(en)
|
2013-02-22 |
2017-12-27 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) molecules containing a 2' internucleoside linkage
|
|
PL2992098T3
(pl)
|
2013-05-01 |
2019-09-30 |
Ionis Pharmaceuticals, Inc. |
Kompozycje i sposoby modulowania ekspresji hbv i ttr
|
|
WO2015061536A1
(en)
|
2013-10-25 |
2015-04-30 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-21 activity
|
|
US10010562B2
(en)
|
2013-11-06 |
2018-07-03 |
Merck Sharp & Dohme Corp. |
Dual molecular delivery of oligonucleotides and peptide containing conjugates
|
|
HUE052709T2
(hu)
|
2014-05-01 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
|
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
US20170304459A1
(en)
|
2014-10-10 |
2017-10-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhalation delivery of conjugated oligonucleotide
|
|
EP3865576A1
(en)
|
2014-12-15 |
2021-08-18 |
Dicerna Pharmaceuticals, Inc. |
Ligand-modified double-stranded nucleic acids
|
|
MX2017011422A
(es)
|
2015-03-17 |
2017-11-10 |
Arrowhead Pharmaceuticals Inc |
Composiciones y metodos para inhibir la expresion del gen del factor xii.
|
|
WO2016196111A1
(en)
*
|
2015-06-01 |
2016-12-08 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting angiotensinogen (agt) and methods of use thereof
|
|
JOP20160211B1
(ar)
|
2015-10-01 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
تراكيب وأساليب لتثبيط تعبير جيني للـ lpa
|
|
MX392014B
(es)
*
|
2015-10-08 |
2025-03-21 |
Ionis Pharmaceuticals Inc |
Composiciones y métodos para modular la expresión de angiotensinógeno.
|
|
TWI859114B
(zh)
|
2016-04-11 |
2024-10-21 |
加拿大商艾爾布圖斯生技公司 |
靶向組合物
|
|
WO2018035380A1
(en)
|
2016-08-17 |
2018-02-22 |
Solstice Biologics, Ltd. |
Polynucleotide constructs
|
|
JOP20170056B1
(ar)
*
|
2016-09-02 |
2021-08-17 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة
|
|
WO2018098328A1
(en)
|
2016-11-23 |
2018-05-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rna agents with reduced off-target effect
|
|
US11015198B2
(en)
|
2017-04-05 |
2021-05-25 |
Silence Therapeutics Gmbh |
Products and compositions
|
|
EP3649243A1
(en)
|
2017-07-07 |
2020-05-13 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing contact-activation pathway-associated diseases using irna compositions targeting factor xii (hageman factor) (f12)
|
|
SG11201912178VA
(en)
|
2017-09-11 |
2020-01-30 |
Arrowhead Pharmaceuticals Inc |
Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
|
|
CN119120476A
(zh)
|
2017-11-13 |
2024-12-13 |
赛伦斯治疗有限责任公司 |
用于抑制细胞中lpa的表达的核酸
|
|
AU2019213004B2
(en)
|
2018-01-29 |
2024-03-07 |
F. Hoffmann-La Roche Ag |
Process for the preparation of GalNAc oligonucleotide conjugates
|
|
WO2019217397A2
(en)
|
2018-05-07 |
2019-11-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for improving strand biased
|
|
TWI851574B
(zh)
*
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
|
AU2019380628B2
(en)
|
2018-11-13 |
2024-10-31 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of LPA in a cell
|
|
SG11202105900UA
(en)
|
2018-12-10 |
2021-07-29 |
Amgen Inc |
CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
|
|
JP7507495B2
(ja)
|
2018-12-28 |
2024-06-28 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
AU2020210900B2
(en)
|
2019-01-22 |
2025-04-24 |
Korro Bio, Inc. |
RNA-editing oligonucleotides and uses thereof
|
|
EP3923989A1
(en)
|
2019-03-21 |
2021-12-22 |
Mitotherapeutix LLC |
Multivalent ligand clusters for targeted delivery of therapeutic agents
|
|
CA3140425A1
(en)
|
2019-05-23 |
2020-11-26 |
Stratos Genomics, Inc. |
Translocation control elements, reporter codes, and further means for translocation control for use in nanopore sequencing
|
|
IL291251B2
(en)
|
2019-09-10 |
2026-06-01 |
Daiichi Sankyo Co Limited |
CONJUGATE OF GalNAC-OLIGONUCLEOTIDE FOR DELIVERY TO LIVER AND MANUFACTURING METHOD THEREOF
|
|
IL292865A
(en)
|
2019-11-13 |
2022-07-01 |
Alnylam Pharmaceuticals Inc |
Methods and preparations for the treatment of angiotensinogen-related disorder - (agt)
|
|
JP7827623B2
(ja)
|
2019-12-09 |
2026-03-10 |
アムジエン・インコーポレーテツド |
LPA発現を阻害するためのRNAiコンストラクト及び方法
|
|
JP2023515664A
(ja)
|
2020-03-06 |
2023-04-13 |
アリゴス セラピューティクス,インコーポレーテッド |
修飾された短い干渉核酸(siNA)分子およびそれらの使用
|
|
US11649458B2
(en)
*
|
2020-05-05 |
2023-05-16 |
University Of Kentucky Research Foundation |
Inhibiting angiotensinogen to attenuate aortic pathology in Marfan syndrome
|
|
MX2022014606A
(es)
|
2020-05-22 |
2023-03-08 |
Wave Life Sciences Ltd |
Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
|
|
WO2022028457A1
(zh)
|
2020-08-04 |
2022-02-10 |
上海拓界生物医药科技有限公司 |
抑制凝血因子XI表达的siRNA、组合物及其医药用途
|
|
KR20250077604A
(ko)
|
2020-08-05 |
2025-05-30 |
다이서나 파마수이티컬, 인크. |
Lpa 발현을 저해하기 위한 조성물 및 방법
|
|
EP4229201A1
(en)
|
2020-10-16 |
2023-08-23 |
Sanofi |
Rna compositions and methods for inhibiting lipoprotein(a)
|
|
CN114763547A
(zh)
|
2021-01-14 |
2022-07-19 |
施能康生物科技有限公司 |
靶向血管紧张素原的核酸及其用途
|
|
CN116761616A
(zh)
*
|
2021-01-22 |
2023-09-15 |
阿耐拉姆制药公司 |
经修饰的双链寡核苷酸
|
|
EP4176061A1
(en)
|
2021-01-30 |
2023-05-10 |
E-Therapeutics plc |
Nucleic acids containing abasic nucleotides
|
|
WO2022232650A1
(en)
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
IL309296A
(en)
|
2021-06-30 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Methods and compositions for the treatment of angiotensinogen-related disorder (AGT-)
|
|
CA3228255A1
(en)
*
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing angiotensinogen (agt)
|
|
US20250283076A1
(en)
|
2021-09-14 |
2025-09-11 |
Argonaute RNA Limited |
Treatment of cardiovascular disease
|
|
WO2023041079A1
(zh)
|
2021-09-18 |
2023-03-23 |
上海金中锘美生物医药科技有限公司 |
Lpa抑制剂及其用途
|
|
US20240401045A1
(en)
|
2021-10-01 |
2024-12-05 |
Adarx Pharmaceuticals, Inc. |
Angiotensinogen-modulating compositions and methods of use thereof
|
|
CN113862268B
(zh)
*
|
2021-10-20 |
2025-05-13 |
厦门甘宝利生物医药有限公司 |
Agt抑制剂及其用途
|
|
KR20240103025A9
(ko)
|
2021-11-16 |
2025-12-10 |
상하이 아르고 바이오파마슈티칼 씨오., 엘티디. |
안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
|
|
TW202345865A
(zh)
|
2022-01-24 |
2023-12-01 |
大陸商上海舶望製藥有限公司 |
抑制LPA(Apo(a))蛋白表達的組合物和方法
|
|
IL315862A
(en)
*
|
2022-04-01 |
2024-11-01 |
Adarx Pharmaceuticals Inc |
Angiotensinogen modulators and methods of using them
|
|
WO2024013334A1
(en)
*
|
2022-07-15 |
2024-01-18 |
Silence Therapeutics Gmbh |
Nucleic acids for inhibiting expression of agt in a cell
|
|
WO2024031101A1
(en)
*
|
2022-08-05 |
2024-02-08 |
Sanegene Bio Usa Inc. |
Double stranded rna targeting angiotensinogen (agt) and methods of use thereof
|
|
TW202430193A
(zh)
|
2022-12-20 |
2024-08-01 |
美商靖因藥業(上海)有限公司 |
靶向agt之聚核酸分子及其用途
|
|
WO2024187193A2
(en)
|
2023-03-09 |
2024-09-12 |
Basecure Therapeutics Llc |
Compositions and methods for inhibition of expression of angiotensinogen (agt) genes
|